Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024

Core Insights - Pulmonx Corporation presented clinical data demonstrating the safety and effectiveness of the AeriSeal® System, with 77.6% of patients converting from collateral ventilation positive (CV+) to collateral ventilation negative (CV-) [1][3] - The 5-year follow-up data from the LIBERATE study showed that patients treated with Zephyr® Valves experienced durable improvements in lung function and quality of life [1][5] AeriSeal CONVERT Trial - The CONVERT trial included 101 patients with severe emphysema and collateral ventilation, showing that 77.6% successfully converted to CV- after treatment with the AeriSeal System [3][8] - Post-conversion, patients treated with Zephyr Valves exhibited an improvement in lung function of 80 mL or 10.2% as measured by Forced Expiratory Volume in 1 second (FEV1) [3] - Quality of life improved by 6.3 points on the St. George's Respiratory Questionnaire, and a mean treated lobe volume reduction (TLVR) of over one liter was observed at 45 days [3] LIBERATE Study 5-Year Follow-Up - The 5-year follow-up data indicated annual improvements in FEV1 ranging from 109 mL in Year 1 to 79 mL in Year 5, demonstrating the long-term benefits of Zephyr Valves [5][6] - The study reported a 38% mortality rate over the 5-year period, which is lower than the 49% mortality in historical medically managed control patients [6] Future Developments - Pulmonx is advancing the CONVERT II trial, expected to enroll approximately 200 patients, to further evaluate the AeriSeal System's effectiveness in limiting collateral ventilation [4][10] - The AeriSeal System has received a "Breakthrough Device" designation from the FDA, although it is not yet approved for commercial sale in the U.S. [9] Zephyr Valves Overview - Zephyr Valves are a minimally invasive treatment option for severe COPD/emphysema, designed to improve lung function and quality of life by blocking off diseased lung portions [11][12] - The valves are included in global treatment guidelines and have been used in over 40,000 patients worldwide [11][13]